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ABSTRACT 
Objective: Zolmitriptan, a class of antidepressant drugs with poor bioavailability due to its first-pass metabolism. The aim of this study was to improve 
systemic bioavailability and explore the brain targeting impact of nasal Zolmitriptan (Zol) solid lipid nanoparticles (SLNs) gel for migraine treatment.  
Methods: Stearic acid and cholesterol used as solid lipid and lecithin as a surfactant, emulsion solvent evaporation technique was used to produce 
Zolmitriptan SLNs. (Zol) SLNs were characterized for particle size, percent entrapment efficiency and in vitro drug release. Formula S6 showed 
greater percent entrapment efficiency (PEE), adequate particle size and sustained drug release behavior. Formula S6 was integrated into HPMC gel 
(3%) to prepare nasal gel. Zol SLN nasal gel was subjected to histopathological study to ensure brain targeting.  
Results: 
Conclusion: Intranasal administration of Solid lipid nanostructure of Zolmitriptan through the olfactory pathway in which it travels from the nasal 
cavity to brain tissue achieved drug targeting potential of about 90% compared with conventional Zolmitriptan tablets. The small particle size 
helped them to squeeze themselves through the small opening in the olfactory neurons to the brain via different endo-cystic pathways of neuronal 
cells in nasal tissue membranes. 
It was observed that all prepared Zol SLNs were in the nano-sized range with a polydispersity index of<0.5. In the cholesterol/lecithin 
combination, higher PEE%, better stability, and less agglomeration inclination were discovered. Results of the release profiles showed that 
developed Zol-SLNs were able to release Zolmitriptan in a sustained manner. Histopathological study of the brain tissues showed that Zolmitriptan 
SLN nasal gel can reach brain cells and localized for 24 h although the hydrophobicity of the target drug.  
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INTRODUCTION 
Migraine is a disabling neurovascular disease with mostly unilateral 
throbbing headaches with a host of neurological symptoms including 
hypersensitivity to light, sound, smell, nausea and variety of 
autonomic and cognitive, emotional and motor disturbances [1]. 
Migraine mechanism suggests that vasoactive peptides will be 
released early in the attack from the primary sensory nerve terminals 
that innervate meningeal blood vessels. These peptides activate 
perivascular trigeminal nerves and cause dilatation of arteries in the 
meninges as well as perivascular inflammation and extravasation of 
plasma proteins [2]. Several triptans are 5HT1B/1D receptor agonists 
commonly prescribed for migraine headaches. Zolmitriptan is 4(S)-4-
[3-(2-dimethyl aminoethyl)-1H5-indolyl-methyl]-1,3-oxazolan 2 one, 
potent and selective serotonin (5-HT1B/1D) receptor agonist which 
causes vasoconstriction of the blood vessels of the brain [3]. Also, 
reducing sterile inflammation associated with zolmitriptan antidromic 
neuronal transmission is another mechanism by which acute migraine 
attacks have been reported to be relieved [4]. It is currently available 
as a conventional tablet, an orally disintegrating tablet and a nasal 
spray (2.5 mg and 5 mg per dose) [5]. Zolmitriptan's absolute 
bioavailability is up to 40% for both oral and nasal dosage forms and 
has a very brief half-life of 1-2 h with first-pass metabolism and rapid 
hepatic and renal clearance. This makes the oral route unsatisfactory 
[6]. Zolmitriptan nasal spray administration resulted in a quicker 
onset of action. However, clinical evidence shows no significant 
improvement in other pharmacokinetic parameters, such as half-life, 
bioavailability and therapeutic gain, over the oral dosage 
forms [4]. For these reasons, our objective was to overcome the above-
mentioned drawbacks by formulating Zolmitriptan's nasal gel delivery 
system for brain targeting. 
Solid Lipid Nanocarriers (SLNs) enhance the permeability of drugs 
owing to lipid and surfactant content and thus improve bioavailability 
through oral, parenteral, dermal, nasal, ocular and pulmonary routes 
of administration due to their tiny size [11]. Their nano-size enables 
them to be transcellular transported to the brain via olfactory neurons 
through the different endocytic pathways of neuronal cells in the 
olfactory membrane [12]. We aimed to improve the systemic 
bioavailability of Zol due to the first-pass metabolism and explore the 
brain targeting the impact of nasal Zol (SLNs) gel for migraine 
treatment.  
The present research focuses on the design 
of Zolmitriptan solid lipid nanoparticles (SLNs) to be delivered to the 
brain via an intranasal route. Solid lipid nanoparticles provide an 
enhancement of nose-to-brain drug delivery as they enable 
hydrophilic molecules to pass through the lipophilic BBB. They can 
also safeguard the encapsulated drug against biological and/or 
chemical degradation [7]. The delivery of drugs to the brain is a major 
challenge owing to the presence of the blood-brain barrier (BBB) [8]. 
Various techniques have been used to enhance drug delivery to the 
brain. One of these techniques includes nanotechnology-based drug 
transport. The intranasal route used for the delivery of many drugs to 
the central nervous system (CNS) [9]. Intranasal delivery does not 
require any modification of drugs [10].  
 
Scheme 1: Zolmitriptan structure 
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MATERIALS AND METHODS 
Materials 
Zolmitriptan, HPMC E15 and Trimethylamine were kindly given as a 
blessing from Pharmaceutical Industries, EIPICO (Cairo, Egypt). 
Dimethylsulfoxide (DMSO), Stearic acid, Cholesterol, and Lecithin 
were acquired from Sigma Aldrich (St. Louis, USA).  
Methods 
Formulations investigated in the present work are listed in [table 1]. 
The blank-and-drug loaded SLNs were prepared by the emulsion 
solvent evaporation method (o/w) followed by homogenization [13-
15].
Formulation of SLNs of zolmitriptan  
 Stearic acid or Soy lecithin and cholesterol mixture were 
accurately weighed and dissolved in 10 ml DMSO as the internal oil 
phase. Then heated above the melting point of lipid at 70 °C. An 
aqueous surfactant solution of zolmitriptan was prepared by 
dissolving zolmitriptan in 5 ml methanol and adding it with tween 
80 to 20 ml water. The organic phase was then poured drop by drop 
into a homogenizer tube containing 20 ml of the hot aqueous phase. 
The mixture was then homogenized (Remi Instruments Pvt. Ltd, 
Mumbai, India) for 30 min at 3000 rpm to form a primary emulsion 
(o/w) and stirred to extract the organic solvent into the continuous 
phase and for proper solidification of SLNs. The stirring was 
continued (2–3 h) at 3000 rpm to get SLN dispersion. 
Zolmitriptan percentage entrapped in SLNs and the amount released 
was measured utilizing a UV spectroscopy (Jenway spectrophotometer, 
Model 6105UV/Vis, England). The maximum absorption of Zolmitriptan 
in phosphate buffer pH 6.8 was found to be at 283 nm [16, 17]. 
Zolmitriptan calibration curve in pH 6.8 phosphate buffer at a range of 1-
10 ug/ml at 283 nm was plotted. The specificity of the analytical method 
was accomplished using a blank formula (Blank SLNs) prepared from all 
the excipients used except drug to verify whether any element of the 
formulation or dissolution medium could interfere with the absorption 
of Zolmitriptan at a chosen wavelength. 
The standard calibration curve and specificity of the analytical 
method used for Zolmitriptan determination 
A volume of 2 ml of each Zolmitriptan loaded SLNs was centrifuged at 
15000 rpm for 45 min to separate the lipid and aqueous phase. The 
supernatant was then diluted with methanol and filtered through 40 um 
filter paper. The amount of unentrapped Zolmitriptan in the supernatant 
was determined spectrophotometrically at λ
Percent entrapment efficiency (PEE) of zolmitriptan in SLNs 
max 
EE% = 
283 [18]. The EE 
percentage was calculated using the following equation where Wi is the 
amount of initial drug and Wf is the amount of free drug: [19, 20]. PEE 
values given are the averages of three estimations. 
 x100 
Particle size estimation of the dispersions performed utilizing a 
Zeta-sizer 3000 PCS (Malvern Instr., England) outfitted with a 5mW 
helium-neon optical device. Estimations were made at 25 °C, edge 90 
°, run time in any event 180 sec. The samples were appropriately 
dispersed in deionized water preceding the estimations. The particle 
size values given are the averages of 3 estimations over 5 min each. 
Particle size, polydispersity index (PDI) and zeta potential 
analysis 
It is an ultra-high-resolution scanning probe microscopy (SPM). The 
morphology of SLNs was examined by (AFM) (Nanosurf Easyscan 2 
AFM). The experiments were conducted in the water at room 
temperature (20±1 °C) under atmospheric pressure operating in 
non-contact mode. For this analysis, triangular silicon tips have been 
used. This cantilever's resonant frequency was about 120 kHz. 
Atomic force microscopy (AFM) 
TEM (Philips, Tecrai10, Dutch) was used to examine the shape and 
surface morphology of the prepared zolmitriptan SLNs using a 
300mesh carbon-coated copper grid and phosphotungstic acid (1%; 
w/v) as a negative stain. After being stained, samples were allowed 
to dry at room temperature for 10 min for investigation. 
Transmission electron microscopy (TEM) 
Scanning electron microscopy (SEM) was used to study the 
morphological characteristics and texture of SLNs by JSM5910 
(JEOL, Japan). SEM micrographs were recorded at a magnification of 
60,000x and an accelerating voltage of 20 kV. 
Scanning electron microscopy (SEM) studies 
Using FT-IR studies (IR Prestige 21 Shimadzu, Japan) the potential 
interaction between the solid lipid core and the incorporated drug 
was investigated. The FT-IR analysis of Zolmitriptan, physical 
mixtures and zol loaded SLNs in a ratio of 1:1), blank-SLNs were 
performed with a resolution of 2 cm
Fourier transfer infrared (FT-IR) spectroscopy studies 
−1 in the range between 4,000 
and 500 cm−1. 
In vitro drug release of zolmitriptan from SLNs 
The 
and kinetic 
analysis of the release data 
in vitro drug release of Zolmitriptan from SLNs was performed 
utilizing the dialysis bag technique [21]. In 12 h distilled water 
presoaked cellulose dialysis bag (cellulose membrane, 12,000-14000 
D cut off molecular weight, Visking®, Medicell, London, UK), 
Zolmitriptan loaded SLNs dispersion equivalent to 10 mg of 
Zolmitriptan were accurately weighed and placed inside the dialysis 
bag and both ends of the bag were strongly closed. The bag was 
immersed into a beaker containing 50 ml phosphate buffer solution 
(PBS) of pH 6.8 which served as the receptor cell and placed in a 
shaker water bath at 37±0.5 °C and agitated at 100 rpm [22]. At time 
intervals from 0.5 to 5 h, 3 ml were removed from the receptor cell for 
each sample and replaced by equivalent volumes of the fresh release 
medium and maintained at a similar temperature. Tests were 
estimated spectrophotometrically at λmax 283 nm against equivalent 
phosphate buffer as a blank using Jenway spectrophotometer (Model 
6105UV/Vis, England) [23]. The quantities of the released drug were 
calculated on the idea of the previously made calibration curve. 
Triplicate samples were analyzed and the average concentration was 
adopted. In vitro drug release data of Zolmitriptan from prepared SLNs 
were fitted to various kinetic models and analyzed to explain the 
mechanism of drug release. 
The selected Zolmitriptan loaded SLN formula (S6) was evaluated for 
stability by storing and sealing in well-closed containers at 5±1, 25±1 
and 45±1 °C for three weeks. The stability study was performed 
according to different parameters including; physical appearance, %EE, 
particle size (PS), and zeta potential (ZP). The changes in %EE, particle 
size, and zeta potential against storage time were monitored.  
Physical stability studies 
Formulation of zolmitriptan loaded SLNs 
Formulation of Zolmitriptan loaded SLN that gave maximum 
entrapment, small particle size, small PDI, high zeta potential and 
better-sustained release effect was selected for preparation nasal gel 
(Tables 2 and 3). HPMC E15 polymer was used as a gelling agent for 
SLNs dispersion. A 3% concentration of HPMC E 15 polymer was used. 
HPMC E15 was added to the nanoparticle dispersion under overhead 
stirring at 250 rpm then, the dispersion was neutralized using 0.05% 
(w/w) triethanolamine. The gel was allowed to stand overnight to 
remove the entrapped air. The same gel formula was used to prepare a 
control gel containing pure drug at the same concentration.  
gel 
Characterization of Zol SLNs nasal gel 
Visual appearance, pH and drug content 
Visual appearance was observed for the detection of any particular 
matter. The pH was measured using a calibrated digital pH meter 
(Model 420, ORION, USA) utilizing a pH of 4.0 and 7.0 standard 
buffers before use. The pH was noted by bringing the electrode close 
to the surface of the formulations and allowing it to equilibrate for 
one minute. The pH of the gel was measured at 25 °C. Gel was then 
diluted with methanol and filtered through 40 um filter paper. The 
of zolmitriptan loaded 
SLNs nasal gel 
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amount of Zolmitriptan was determined spectrophotometrically at λ 
max 283 to determine drug content. 
Viscosity study of zolmitriptan loaded SLNs nasal gel 
Viscosity of the gel was measured on Brookfield viscometer (DV-
II+Pro Viscometer, Middleboro, USA). The gel formula was placed in 
a small sample adaptor, and the viscosity was measured using 
spindle LV-63 at 20 rpm.  
In vitro drug release study 
The dialysis bag diffusion was used to study Zolmitriptan loaded 
SLNs gel in vitro release. Zolmitriptan loaded SLNs gel (equivalent 
to10 mg of the drug) were put in the dialysis bag. The method was 
performed as shown before at time intervals from 1 to 24 h, a 
placebo SLNS gel experiments were conducted. Samples were 
removed at predetermined time intervals from the receptor 
compartment and replaced by the fresh medium. The dissolved drug 
quantity was determined with UV spectrophotometry at λmax 283 
nm against a blank. All experiments were performed in triplicate.  
1-Group I: received plain gel (3% of HPMC E 15 gel without drug) to 
serve as a negative control group and sacrificed after 1 hour. 
Histopathological study of brain tissue 
In vivo histopathological study of brain tissues carried out of the 
previously chosen S6 zolmitipitan SLNs gel and plain gel (3% of 
HPMC E 15 gel without drug) on male albino rats (adult/weighing 
200–250 g). The protocol of the study was approved by the October 
University of Modern Science and Arts (MSA) Ethics Committee 
(PT8/ec8/2018f). The animals were kept under standard laboratory 
conditions, received a balanced diet of commercially available pellet 
rat feed, water and libitum, i.e. temperature of 22±3 _C and relative 
humidity of 30–70% under a 24-hour light/dark cycle. The animals 
were housed in polypropylene cages, four animals per cage with free 
access to standard laboratory diet and water. 
2-Group II: received SLNs zolmitriptan gel for S6 and sacrificed after 
1 hour  
3-Group III: received plain gel (3% of HPMC E 15 gel without drug) 
to serve as a negative control group and sacrificed after 4 h 
4-Group IV: received SLNs zolmitriptan gel for S6 and sacrificed 
after 4 h. 
5-Group V: received plain gel (3% of HPMC E 15 gel without drug) to 
serve as a negative control group and sacrificed after 24 h. 
6-Group VI: received SLNs zolmitriptan gel for S6 and sacrificed 
after 24 h.  
Rats were sacrificed using thiopental (50 mg/kg) and brains were 
removed, cleaned with cold saline (0.9%). Brain tissues fixed in 10% 
formalin and embedded in paraffin wax were sonicated at 6 µm 
thickness on a rotatory microtome, then stained with eosin and 
hematoxylin [24]. The stained sections were observed using the 
digital microscope and digital photomicrographs by using the 
attached camera. 
Statistical analysis was performed using the GraphPad Prism version 
8.1.2 software utilizing analysis of variance (ANOVA) or the paired t-
test, where appropriate, and statistical significance was set at 
𝑃𝑃<0.05. 
Statistical analysis 
RESULTS AND DISCUSSION 
Zolmitriptan exhibits its maximum absorption at 283 nm and 
obeyed Beer's law in the range of 1-10 µg/ml. There was a good 
linear relationship between the Zolmitriptan concentration and its 
absorption (R
The standard calibration curve and specificity of the analytical 




Table 1: Formulation of SLNs of zolmitripta
Ingredients 
n 
Quantities % (W/W)   
S1 S2 S3 S4 S5 S6 
Zolmitriptan (mg) 100 100 100 100 100 100 
Stearic acid (mg) 1000 1250 1500 - - - 
DMSO (ml) 10 10 10 10 10 10 
Cholesterol (mg) - - - 125 200 250 
Tween 80 (ml) 2 2 2 2 2 2 
Lecithin - - - 25 50 75 
Double distilled water (ml) 30 30 30 30 30 30 
 
The formulations could be arranged in descending order according 
to PEE as follows: S1 (40.87±7.25 %)>S2 (55.04±6.14%)>S3 
(58.97±9.87%)>S4 (65.32±5.25%)>S5 (78±4.25%)>S6 (82.45±4.25 
%) as shown [table 2]. We noticed that PEE % was increased by 
raising the lipid concentration (stearic acid and cholesterol). This 
may be because the quantity of lipids used in low concentration 
formulae is not adequate to entrap the drug, while higher 
concentration formulae have an adequate lipid to entrap the 
accessible drug and thus produce maximum PEE%. Singh et al. noted 
that owing to more lipid accessibility, the rise in lipid quantity to the 
optimum level improves the PEE% in order to entrap the drug [25] 
also, the lipid types highly affected the PEE%. The mixture of 
cholesterol and lecithin showed significantly greater levels of PEE 
than stearic acid (S4, S5 and S6) at p<0.001. It could be explained by 
the length of cholesterol is about 13.8A˚, which is much shorter than 
the length of stearic acid. A shorter length could generate more 
random molecular packing, allowing more space to drug 
accommodation [26]. The increase in drug entrapment efficiency 
might be also, due to lecithin effect: high Tc (phase transition 
temperature), decrease in membrane permeability, therefore, 
preventing drug leakage, hence the increase in Zolmitriptan content 
within the prepared SLN [27]
Percent entrapment efficiency (PEE %) of zolmitriptan in SLNs 
. Vijayan et al. showed that the 
entrapment efficiency (%) was directly proportional to lecithin 
concentration and obviated that low entrapment efficiency was due 
to low affinity between drugs at different solvent (organic and 
aqueous) [13]. 
 
Manjunath and his colleague revealed that the 
entrapment efficiency of the drug in the lipids depended upon the 
variable characters such as miscibility, the solubility of the drug in 
the lipid melt, physical and chemical structure of the lipid matrix and 
crystalline state of lipid components [28]. Varshosaz et al. showed 
that by increasing the amount of cholesterol in SLN, the PEE is much 
increased [29]. 
Formulae 
Table 2: PEE, Z-average, PDI and zeta potential of SLNs 
S1 S2 S3 S4 S5 S6 
Percent Entrapment efficiency (PEE)±SD 40.87±7.25 55.04±6.14 58.97±9.87 65.32±5.25 78±4.25 82.45±4.25 
Z-average (nm)±SD 144.9±40.3 218.5±23.3 205.8±16.9 469.5±26.1 581.2±29.6 248.8±9.1 
Polydispersity index (PDI)±SD 0.596±0.05 0.813±0.05 0.347±0.03 0.2±0.06 0.631±0.02 0.371±0.05 
Zeta potential±SD -12.1±1.02 -12.6±1.56 -13.4±0.97 -20±1.47 -15.7±1.03 -14.2±1.56 
mean±SD, n=3 
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Particle size measurement was done to ensure that particles of the 
Zol-SLNs in the nanometer range. We observed that all prepared 
SLNs were in the nano-sized range (average particle size values 
ranged from 144.9±40.3 nm to 581.2±29.6 nm), with a 
polydispersity index of<0.5 as shown in [table 2]. The particle size 
increased significantly with the increase of lipid concentration 
(Stearic acid and cholesterol) at p<0.0001. The results indicate that 
the amount of stearic acid has a positive influence on the mean size 
of the SLN. It is logical that increased particle size was observed with 
higher amounts of stearic acid. Lack of sufficient surfactant to cover 
the particle surface is the likely reason for increased particle size 
[30]. The particle size of SLNs prepared from the combination of 
cholesterol and lecithin was significantly greater than those 
prepared from stearic acid at p<0.0001, but by increasing the 
concentration of lecithin to 75 mg it showed a greater reduction in 
particle size of cholesterol SLNS to 248.8±9.1 at p<0.0001, which 
could be attributed to the excessive surfactant molecules present 
rapidly cover the new surfaces reducing the surface tension and thus 
facilitating the particle partition during emulsification[31]. As a 
result, an increase in the concentration of surfactant (Lecithin) 
results in a reduction in the SLN particle size. The interaction 
between cholesterol and surface-active agent might increase in 
surface curvature of oil droplets and leading to the small size of SLN 
after cooling down [32]. Jain et al. observed that lecithin addition 
prevents the agglomeration of particles [33]. Measuring zeta 
potential allows for predictions of colloidal dispersion storage 
stability [33]. Particle aggregation is less likely to occur for charged 
particles with high zeta potential due to electric repulsion. 
Compared to SLNs formulations, formulations containing cholesterol 
and lecithin combination showed a significant greater zeta potential 
values at p<0.01 as shown in table 2. Severino et al. showed that 
stearic acid nanoparticles were negatively charged, but the zeta 
potential was rather low [34].  
Particle size, polydispersity index (PDI) and zeta potential analysis 
AFM images of Zolmitriptan loaded SLN showed that lipid 
composition did not influence nanoparticle morphology. 
Nanoparticles appeared in [fig. 1] to be round-shaped and SLN's 
mean particle diameter appeared to be smaller (around 150 nm) 
compared to the particle size estimate. Additionally, no roughness is 
observed on the particle surface. 
Atomic force microscopy (AFM) 
 
 
Fig. 1: AFM microphotographs of SLN 
 
 
Fig. 2: Transmission electron micrograph of zolmitriptan loaded SLNs (S6) 
 
Transmission electron microscopy (TEM) 
TEM micrographs revealed the formation of nanoparticles of narrow 
particle size distribution [fig. 2]. Micrographs showed that the SLN 
were smooth, spherical and homogenous nanovesicles. 
Scanning electron microscopy (SEM) studies 
Fig. 3 showed a smooth and spherical shape of the particles. Also, 
particles generally agglomerated owing to carriers ' lipid nature, 
surfactant presence, and sample preparation before SEM analysis. 
Zolmitriptan and lipid compatibility studies were carried out by 
FTIR, and the results were given in [fig. 4]. The pure zolmitriptan 
exhibits characteristic peaks at 3352 cm
Fourier transfer infrared (FT-IR) spectroscopy studies 
-1 corresponding to the 
aromatic secondary amine N-H stretching, 2974.23 cm-1 
corresponding to aromatic C-H stretching, 1735.93 cm-1 
corresponding to C=O stretching and 1257.59 cm-1corresponding to 
C-N aliphatic amine stretching) as appeared in fig. 4. The FTIR 
spectra of Zolmitriptan and lipid physical mixture (cholesterol, 
Lecithin and stearic acid) exhibit the same characteristic peaks due 
the aromatic secondary amine N-H stretching at 3348.42 cm-1, C = O 
stretching at 1735.93 cm-1, and C-N aliphatic amine stretching at 
1257.59, However they showed a slight shift in aromatic C-H 
stretching at 2931.8, 2978.09 and 2920.52 cm-1 respectively. Thus, 
it is evident that all the characteristic peaks that were present in the 
spectra of pure drugs replicated almost in the same region in the 
spectra of Zolmitriptan and lipid physical mixture (cholesterol, 
Lecithin, and stearic acid) indicating that there is no significant 
interaction between the drugs and the lipids. 
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4: FTIR spectrum of zolmitriptan, lipids, and their physical mixture 
In vitro release of zolmitriptan from SLNs and kinetic analysis 
of the release data 
In vitro
Cholesterol SLNs exhibited significantly higher initial burst release 
than Stearic acid at p<0.01 and both followed by sustained release. 
The initial burst effect was ranged from (22.01±1.23 to 41.34±1.56) 
within one hour. The initial 
 drug release from the Zolmitriptan loaded SLNs was 
performed in PBS (pH 6.8 at 37 °C) using the dialysis bag technique 
over 5 h and the cumulative release percentages are illustrated in 
[fig. 5]. The release profiles of the investigated SLN formulations 
shows a biphasic behavior, an initial fast release that lasted for 0-1 h, 
followed by a sustained slow release behavior. Burst release can be 
useful to improve the penetration of the drug, while, sustained-
release supplied the drug over a prolonged period [33].  
in vitro burst release was probably caused 
by the drug adsorbed on the nanoparticle surface or precipitated from 
the superficial lipid matrix [35]. Muntimadugu E et al. reported that 
initial burst release was mainly due to weakly bound drug on the 
surface of nanoparticles [36]. Baig et al. reported that the initial burst 
release rate was affected by the change of concentration of the lipid 
(Stearic acid and cholesterol) and surfactant (Lecithin) in the external 
phase. When the lipid concentration increased, the initial burst release 
rate decreased. Whereas surfactant concentration increases, the initial 
burst release rate increases due to the increased solubility of the drug 
in the external phase [37]. SLNs showed prolonged cumulative drug 
release percent and it decreased with increasing lipid concentration as 
shown in fig. 5. Due to the high concentration of drug in the inner 
phase [38]. The drug release of Zolmitriptan loaded SLNs was ranged 
from 50.24±5.6to 75.75±5.6 at 5 h SLNs suggests homogeneous 
entrapment of the drug throughout the systems. Furthermore, in 
vitro release profiles for the selected prepared SLNs were applied on 
various kinetic models (zero-order, first-order, and Higuchi 
equations), to fig. out the mechanism of drug release. The 
highest r value for drug release was obtained for Higuchi’s equation at 
0.975, 0.885, 0.916, 0.9655, 0.976 and 0.965 for S1, S2, S3, S4, S5 and 
S6 respectively. Release pattern of the drug from almost all SLNs 
formulations was best fitted into the Higuchi equation that describes 
the diffusion of the drug from homogenous and granular matrix 
systems [35]. Considering these observations, it was concluded that all 
the batches of SLNs had the potential for sustained drug delivery. This 
finding is in good agreement with the previous studies [39, 13]
Formulation of Zolmitriptan loaded SLNs that gave maximum 
entrapment efficiency percent, small particle size, small 
polydispersity index, high zeta potential, and better-sustained 
release effect were selected for physical stability studies, 
preparation of gel for nasal administration and brain 
histopathological studies. On that basis, we have chosen formula S6 




Fig. 5: In vitro drug release of zolmitriptan from SLNs; 
mean±SD, n=3 
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During the storage period, there was no change in color or creaming 
and phase separation in the S6 formulation. There was a non-
significant increase in particle size of SLN stored at 5 °C, 25 °C and 
45 °C after 3 w at. At greater temperature 45 °C, the entrapment 
efficiency percent was none significantly decreased compared to 
other storage circumstances. The non-significant change in size and 
%EE due to the partial leakage of zolmitriptan from SLN. SLN 
stability also showed a non-significant decrease by raising the 
storage temperature as shown in the zeta potential outcomes. The 
results were presented in [table 3]. 
Physical Stability studies 
 
Table 3: Physical stability studies of SLN
Temperature 
s 




Entrapment efficiency % 
mean±SD 
Zeta potential (mv) 
mean±SD 
5 C ° 240±10.26 0.43±0.88 83±2.56 -19.7±2.7 
25 C ° 254±14.26 0.42±0.76 79±1.94 -16±1.23 
45 C ° 249±22.77 0.41±0.56 76±1.34 -12±1.54 
mean±SD, n=3 
 
Characterization of SLN gel 
Visual appearance, pH and drug content of zolmitriptan loaded 
SLN gel 
The prepared gel of selected Zolmitriptan loaded SLN (S6) was 
white, smooth, homogenous with semisolid consistency, and show 
no syneresis. The pH of the Zolmitriptan loaded SLN formula was 
found to be 6.84±0.18 with drug content in range 9 mg/0.5g of gel 
(90%) as shown in [table 4]. 
Viscosity study of zolmitriptan loaded SLN nasal gel 
The viscosity of Zolmitriptan loaded SLN nasal gel (gelled with HPMC 
E15) was recorded to be 3000 cp as shown in [table 4]. It has to be noted 
that the viscosity of the gels is due to the polymer (HPMC E15) used.  
The gel showed an initial burst release of drug during the first 1 
hour as discussed before. Following that, the drug entrapped into 
the gel was released gradually as shown in [fig. 6]. About 
73.21±1.44%, 75.32±2.54% were released after 12 and 24 h 
respectively. 
In vitro release study 
In vitro release profiles for Zolmitriptan loaded SLN 
nasal gel was applied on various kinetic models (zero-order, first-
order, and Higuchi equations), to fig. out the mechanism of drug 
release. The highest r value for drug release was obtained for 
Higuchi’s equation at 0.967 compared to that of zero-order at 0.838 
and first order at 0.912. The mechanism of drug release was found 
to be Higuchi model. We concluded that Zolmitriptan loaded SLN 
nasal gel 
 
has a sustained drug release effect. This finding is in good 
agreement with the previous studies [39, 13]. 
Parameter 
Table 4: Zolmitriptan loaded SLN nasal gel characterization 
Zolmitriptan loaded SLNs nasal gel 
Visual Examination White color with Good appearance 
PH 6.84±0.18 
Drug Content 90%±7.25 






6: In vitro drug release of zolmitriptan from SLNs nasal gel; mean±SD, n=3 
Histological examination of brain tissue 
Histopathological analysis was conducted on sections of brain tissue 
treated with formula S6 Zolmitriptan SLNs gel and control plain gel 
(3% of HPMC E 15 gel) free from drug at a different time interval 
[fig. 7]. Histopathological examination of hippocampus normal 
pyramidal cells of brain tissue, (a) show no appearance of the drug 
after 1hour while, (b) showed a slight difference in cells 
condensation in CA2 layer after 1 hour. (C) Showed CA2 region with 
the intact pyramidal cell after four hours. While; (D) show a slight 
difference in cells structure in CA2 layer after four hours. (e) 
Showed normal neurons (arrowhead) and white matter (arrow) 
after 24 h. (f) Showed spots of the drug appear around the cell after 
24 h. These promising results ensure that zolmitriptan drugs 
achieve higher brain targeting with 24 h which helps us to enhance 
efficacy in the treatment of migraine headaches specially that many 
patients suffer from nausea and/or vomiting that can make the oral 
treatment ineffective. 
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Fig. 7: Photomicrograph of a section of the brain of rat (a) received plain gel to serve as a negative control group and sacrificed after 1 
hour. (b) Received SLNs zolmitriptan gel and sacrificed after 1 h. (C) Received plain gel to serve as a negative control group and sacrificed 
after 4 h. (D) Received SLNs zolmitriptan gel and sacrificed after 4 h. (e) Received plain gel to serve as a negative control group and 
sacrificed after 24 h. (f) Received SLNs zolmitriptan gel and sacrificed after 24 h 
 
Zolmitriptan (Zol) solid lipid nanoparticles (SLNs) gel success to 
reach the brain cells via permeation through nasal mucosa through 
the olfactory region thus; passing hepatic metabolism providing 
anti-migraine activity. The prepared Zol SLNs formulations were 
characterized for various parameters, and maximum entrapment 
efficiency was obtained with small particle size. Sustained release of 
ZMT SLNs was best fitted into the Higuchi equation that describes 
the diffusion of the drug from homogenous and granular matrix 
systems. Histological examination of brain tissue showed that 
Zolmitriptan achieved a higher brain targeting with 24 h, which help 
us to enhance efficacy in the treatment of migraine headaches. 
CONCLUSION 
The brain targeting via nasal drug delivery system circumvent the 
pre-systemic metabolism thus increasing the bioavailability of 
zolmitriptan. Further, future clinical studies should be done on that 
technique to show the significance of an increase in bioavailability 
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